Abstract:Background:The prognosis of adult B‐cell acute lymphoblastic leukemia (B‐ALL) remains poor due to drug resistance and relapse although the remission rate reaches 80%∼90%. Identifying molecular abnormalities associated with important cellular activities may help to improve the B‐ALL risk stratification and provide potential therapeutic targets. We have previously found that the transcript level of Ras‐related dexamethasone‐induced 1(RASD1) is abnormally increased in adult B‐ALL bone marrow mononuclear cells (BMMNCs) by bioinformatics and quantitative PCR, suggesting that it may be involved in the pathogenesis of B‐ALL. RASD1 is a member of the Ras superfamily. Its abnormal expression has been reported in multiple solid tumors. However, its clinical relevance and biological role in hematopoietic malignancies, especially in B‐ALL remain to be elucidated.Aims:To determine the clinical significance of RASD1 transcript levels in adult B‐ALL and to study its biological role and the potential mechanism in B‐ALL.Methods:Quantitative real‐time polymerase chain reaction(RT‐qPCR) was used to detect RASD1 transcript levels in BMMNCs from 90 newly diagnosed Philadelphia chromosome(Ph)‐negative B‐ALL and 40 healthy donors. The correlation between RASD1 transcript levels and relapse was analyzed. The biological function and potential mechanism were studied with RASD1‐overexpressing and knockdown human B‐ALL cell lines constructed by lentiviral infection. A xeno‐transplant mouse model was used to study the effect of RASD1 overexpression on proliferation in vivo.Results:The transcript levels of RASD1 in bone marrow mononuclear cells from 90 Philadelphia chromosome(Ph)‐negative adult B‐ALL (81.76%, 0.22%∼1824.52%) were significantly higher than those of 40 healthy controls (7.59%, 0.46%∼38.66%, P < 0.001). Patients with low RASD1 transcript levels had a significantly higher 5‐year cumulative incidence of relapse (CIR, 52.0% [37.4%, 66.6%] vs. 36.2% [22.2%,50.2%]; P = 0.013) and a lower relapse‐free survival (RFS, 47.5% [32.9%,62.1%] vs. 63.1% [49.0%,77.2%]; P = 0.012) than patients with high RASD1 transcription levels. Multivariate analysis showed that low RASD1 transcript level was an independent risk factors for CIR and RFS in patients with Ph‐negative B‐ALL (CIR: HR = 3.367[1.668,6.796], P = 0.001; RFS:HR = 2.938 [1.427,6.047], P = 0.003). Functional analysis showed that overexpression of RASD1 in BALL‐1 and Nalm6 cells inhibited cell proliferation, cell cycle progression and survival after exposure to chemotherapeutics including daunorubicin, methotrexate and cytarabine. In contrast, RASD1 knockdown in Sup‐B15 cells showed the opposite effects. The role of RASD1 in inhibiting cell growth was verified in a tumor‐bearing mouse model. Western Blot showed that overexpression of RASD1 caused decreased levels of mTOR and p70S6K phosphorylation, increased expression of LC3BII/I and Beclin‐1, suggesting that mTOR/p70S6K signaling pathway and autophagy may be involved in RASD1‐mediated regulation of cell proliferation.Summary/Conclusion:The transcript levels of RASD1 in BMMNCs from newly diagnosed Ph‐negative adult B‐ALL were significantly higher than those of healthy controls. A low RASD1 transcript level was independently correlated with a higher CIR and a lower RFS. Overexpression of RASD1 inhibited cell proliferation both in vitro and in vivo. mTOR/p70S6K signaling pathway and autophagy may be involved in RASD1‐mediated regulation of proliferation in B‐ALL cells.image

The Clinical Significance and Biological Function of DPEP1 in B-cell Acute Lymphoblastic Leukemia

DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia

Dehydropeptidase 1 Promoted Survival And Cell Cycle Progression Through Regulation Of Creb And P53 Pathways In B-Cell All

Expression and Clinical Significance of Phospholipase D1 in De Novo Acute Myeloid Leukemia

Abstract 6311: Clinical assessment of DPEP1 expression and its interacting genes in tumor (T) and adjacent normal tissue (NAT) of colorectal cancer

Prognostic Significance of the Tumor Suppressor Protein P53 Gene in Childhood Acute Lymphoblastic Leukemia.

Overexpression of Lymphoid Enhancer‐binding Factor‐1 (LEF1) is a Novel Favorable Prognostic Factor in Childhood Acute Lymphoblastic Leukemia

Prognostic Value of RASD1 Transcript Levels in Adult Philadelphia-negative B-cell Acute Lymphoblastic Leukemia

Clinical Features and Prognostic Implications of Ecotropic Viral Integration Site 1 (EVI1) in Childhood Acute Lymphoblastic Leukemia

High Expression of EBP is an Adverse Prognostic Factor for De Novo Acute Myeloid Leukemia

Abstract A003: DPEP1 maintains microsatellite stability in colorectal cancer at the tumor microenvironment interface

PF166 RASD1 INHIBITS THE PROLIFERATION OF LEUKEMIA CELLS AND CORRELATES WITH LEUKEMIA RELAPSE IN ADULTS WITH PHILADELPHIA CHROMOSOME‐NEGATIVE B‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Low EVI1 Expression at Diagnosis Predicted Poor Outcomes in Pediatric Ph-negative B Cell Precursor Acute Lymphoblastic Leukemia Patients

Comprehensive Analysis of Expression Profile Reveals the Ubiquitous Distribution of Pppde Peptidase Domain 1, A Golgi Apparatus Component, and Its Implications in Clinical Cancer

Dipeptidase‑2 is a Prognostic Marker in Lung Adenocarcinoma That is Correlated with Its Sensitivity to Cisplatin.

The Genetic Basis of Early T-cell Precursor Acute Lymphoblastic Leukaemia.

PELI2 Regulates Early B-cell Progenitor Differentiation and Related Leukemia Via the IL-7R Expression.

The MRP1 expression in childhood acute lymphoblastic leukemia and its clinical significance

Bioinformatics Analysis Identifies EPAS1 as a Novel Prognostic Marker Correlated with Immune Infiltration in Acute Myeloid Leukemia

mPGES-1/PGE2 promotes the growth of T-ALL cells in vitro and in vivo by regulating the expression of MTDH via the EP3/cAMP/PKA/CREB pathway

Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer